We are live on ! Find out more
LGND icon

Ligand Pharmaceuticals
LGND

357 hedge funds and large institutions have $4.15B invested in Ligand Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 59 funds opening new positions, 133 increasing their positions, 115 reducing their positions, and 43 closing their positions.

New
Increased
Maintained
Reduced
Closed

37% more first-time investments, than exits

New positions opened: 59 | Existing positions closed: 43

22% more call options, than puts

Call options by funds: $8.48M | Put options by funds: $6.95M

16% more repeat investments, than reductions

Existing positions increased: 133 | Existing positions reduced: 115

7% more capital invested

Capital invested by funds: $3.89B → $4.15B (+$264M)

2% more funds holding

Funds holding: 349 → 357 (+8)

0% more funds holding in top 10

Funds holding in top 10: 8 → 8 (0)

0.18% less ownership

Funds ownership: 104.47% → 104.29% (-0.18%)

Holders
357
Holders Change
+8
Holders Change %
+2.29%
% of All Funds
4.39%
Holding in Top 10
8
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
59
Increased
133
Reduced
115
Closed
43
Calls
$8.48M
Puts
$6.95M
Net Calls
+$1.54M
Net Calls Change
-$3.42M

Top Buyers

1
Invesco
Invesco
Georgia
+$60.8M
2
NCGI
Next Century Growth Investors
Minnesota
+$19M
3
Bessemer Group
Bessemer Group
New Jersey
+$16.7M
4
Franklin Resources
Franklin Resources
California
+$15.2M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$12.9M

Top Sellers

1
UBS AM
UBS AM
Illinois
-$29.8M
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$21M
3
Massachusetts Financial Services
Massachusetts Financial Services
Massachusetts
-$18.9M
4
NAMI
Nomura Asset Management International
Pennsylvania
-$14M
5
Goldman Sachs
Goldman Sachs
New York
-$9.48M
Name Holding Trade Value Shares
Change 		Change in
Stake
CGH
201
Crossmark Global Holdings
Texas
$478K +$25.3K +128 +6%
BCM
202
BTC Capital Management
Iowa
$477K +$48.9K +247 +12%
PNC Financial Services Group
203
PNC Financial Services Group
Pennsylvania
$468K +$20.2K +102 +5%
FT
204
Fiduciary Trust
Massachusetts
$465K +$36.4K +184 +9%
ECM
205
Evergreen Capital Management
Washington
$454K – – –
MOACM
206
Mutual of America Capital Management
New York
$450K +$396 +2 +0.1%
CIP
207
Cornerstone Investment Partners
Georgia
$440K +$100K +507 +30%
ATPW
208
Ashton Thomas Private Wealth
Arizona
$438K +$18K +91 +4%
VPIM
209
Vanguard Personalized Indexing Management
California
$432K +$153K +771 +55%
CG
210
Cynosure Group
Utah
$416K +$413K +2,085 New
VF
211
Virtu Financial
New York
$409K +$405K +2,049 New
SLAM
212
Swiss Life Asset Management
$408K +$44.1K +223 +12%
CIM
213
Contravisory Investment Management
Massachusetts
$403K -$3.17K -16 -0.8%
FMI
214
F/M Investments
District of Columbia
$399K -$8.73M -44,129 -96%
1CM
215
1492 Capital Management
Wisconsin
$391K +$16.2K +82 +4%
Truist Financial
216
Truist Financial
North Carolina
$388K +$52.6K +266 +16%
SGI
217
Summit Global Investments
Utah
$387K -$95K -480 -20%
PA
218
Profund Advisors
Maryland
$375K -$70K -354 -16%
KeyBank National Association
219
KeyBank National Association
Ohio
$374K +$78.5K +397 +27%
X
220
Xponance
Pennsylvania
$367K +$59.9K +303 +20%
CB
221
Commerce Bank
Missouri
$360K +$97.7K +494 +38%
CCAL
222
City Center Advisors LLC
Michigan
$358K +$355K +1,795 New
BMO
223
Beck Mack & Oliver
New York
$338K +$335K +1,694 New
Group One Trading
224
Group One Trading
Illinois
$333K -$254K -1,284 -43%
SI
225
Stephens Inc
Arkansas
$324K -$6.13K -31 -2%
7 8
9
10 11

LGND Hedge Fund Activity: Q1 2026 in Review

357 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q1 2026, worth a combined $4.15B — up 6.8% from $3.89B a quarter earlier.

Buyers outnumbered sellers: 59 funds opened new LGND positions and 43 closed out — a net gain of 16 holders — while 133 added to existing stakes and 115 trimmed.

The largest buyer was Invesco, adding an estimated $60.8M. The largest seller was UBS AM, cutting an estimated $29.8M.

  • 357 institutional investors held Ligand Pharmaceuticals (LGND) as of Q1 2026, up from 349 in Q4 2025.
  • Funds reported $4.15B of Ligand Pharmaceuticals stock for Q1 2026, up 6.8% quarter-over-quarter.
  • 59 funds opened new Ligand Pharmaceuticals positions in Q1 2026 and 43 closed out, a net change of +16 holders.
  • The largest Ligand Pharmaceuticals buyer in Q1 2026 was Invesco, an estimated $60.8M added.
  • The largest Ligand Pharmaceuticals seller in Q1 2026 was UBS AM, an estimated $29.8M sold.

Based on aggregated 13F filings for Q1 2026.